Chimerix, Inc.
NASDAQ: CMRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael T. Andriole
- Employees
- 79
- Headquarters
- Durham, United States
- IPO year
- 2013
- Market cap
- $801.1M
- Website
- https://www.chimerix.com
Loading CMRX…
Loading profile data…Frequently asked questions about CMRX
What does Chimerix, Inc. (CMRX) do?
Chimerix, Inc. operates as a biopharmaceutical company, committed to advancing therapeutic solutions that improve the lives of individuals grappling with severe medical conditions. Its sole approved medicine is TEMBEXA (brincidofovir), a lipid conjugate designed to combat smallpox by inhibiting viral DNA synthesis, positioned as a critical medic...
Where does CMRX trade?
Chimerix, Inc. (CMRX) trades on the NASDAQ Global Market.
What sector is CMRX in?
Chimerix, Inc. (CMRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Chimerix, Inc.?
Michael T. Andriole is the chief executive officer of Chimerix, Inc. (CMRX).
Where is Chimerix, Inc. headquartered?
Chimerix, Inc. is headquartered in United States.
Does CMRX pay a dividend?
Chimerix, Inc. (CMRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CMRX go public?
Chimerix, Inc. (CMRX) completed its initial public offering in 2013.